Stephen P. Macmillan net worth and biography

Stephen Macmillan Biography and Net Worth

Chairman, CEO & President of Hologic

Stephen P. MacMillan serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. MacMillan was appointed as President, Chief Executive Officer and a director in December 2013 and was elected Chairman of the Board in June 2015. From October 2012 to December 2013, Mr. MacMillan was the Chief Executive Officer of sBioMed, LLC, a biomedical research company. From 2003 to 2012, he served in various roles at Stryker Corporation, including Chief Operating Officer from 2003 to 2005, Chief Executive Officer from 2005 to 2012 and Chairman from 2010 to 2012. Prior to 2003, Mr. MacMillan was a senior executive with Pharmacia Corporation, where he oversaw five global businesses. Prior to joining Pharmacia, Mr. MacMillan spent 11 years with Johnson & Johnson in a variety of senior roles in both the U.S. and Europe, including as President of its consumer pharmaceuticals joint venture with Merck. Mr. MacMillan began his career with Procter & Gamble in 1985. Mr. MacMillan currently serves on the Board of Trustees of Davidson College. Mr. MacMillan holds a Bachelor of Arts degree in economics from Davidson College, and is a graduate of Harvard Business School’s Advanced Management Program.

What is Stephen P. Macmillan's net worth?: The estimated net worth of Stephen P. Macmillan is at least $82.94 million as of July 17th, 2024. Macmillan owns 1,157,562 shares of Hologic stock worth more than $82,939,317 as of December 21st. This net worth approximation does not reflect any other assets that Macmillan may own. Learn More about Stephen P. Macmillan's net worth.
How do I contact Stephen P. Macmillan?: The corporate mailing address for Macmillan and other Hologic executives is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. Hologic can also be reached via phone at (508) 263-2900 and via email at [email protected]. Learn More on Stephen P. Macmillan's contact information.
Has Stephen P. Macmillan been buying or selling shares of Hologic?: Stephen P. Macmillan has not been actively trading shares of Hologic over the course of the past ninety days. Learn More on Stephen P. Macmillan's trading history.
Who are Hologic's active insiders?: Hologic's insider roster includes Benjamin Cohn (Insider), Sally Crawford (Director), Sean Daugherty (Insider), Charles Dockendorff (Director), Scott Garrett (Director), John Griffin (General Counsel), Stephen Macmillan (Chairman, CEO & President), Essex Mitchell (Insider), Karleen Oberton (CFO), Brandon Schnittker (Division President, Surgical Solutions), Christiana Stamoulis (Director), Kevin Thornal (Insider), Peter Valenti, III (Insider), and Jan Verstreken (Insider). Learn More on Hologic's active insiders.
Are insiders buying or selling shares of Hologic?: During the last twelve months, insiders at the medical equipment provider sold shares 8 times. They sold a total of 75,982 shares worth more than $5,840,923.48. The most recent insider tranaction occured on December, 4th when COO Essex D Mitchell sold 24,856 shares worth more than $1,897,507.04. Insiders at Hologic own 1.8% of the company. Learn More about insider trades at Hologic.
Information on this page was last updated on 12/4/2024.

Stephen P. Macmillan Insider Trading History at Hologic

Stephen P. Macmillan Buying and Selling Activity at Hologic

Hologic Company Overview

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Today's Range

Now: $71.65

$70.36

$71.95

50 Day Range

MA: $78.65

$70.76

$83.72

2 Week Range

Now: $71.65

$70.36

$84.67

Volume

8,560,791 shs

Average Volume

1,672,050 shs

Market Capitalization

$16.26 billion

P/E Ratio

21.52

Dividend Yield

N/A

Beta

0.96

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.